describ
case
child
affect
sever
combin
immunodefici
scid
adenosin
deaminas
ada
defici
show
matern
tcell
engraft
find
never
report
presenc
engraft
matern
cell
mislead
although
ada
enzymat
level
suggest
adascid
child
present
classic
sign
ada
defici
therefor
initi
diagnosi
convent
scid
howev
ada
toxic
metabolit
molecular
character
confirm
diagnosi
polyethylen
glycolmodifi
bovin
peg
ada
therapi
progress
decreas
number
matern
engraft
cell
child
graft
full
bone
marrow
match
unrel
donor
reduc
condit
regimen
result
complet
immunolog
reconstitut
matern
cell
fetal
perinat
transplacent
passag
identifi
patient
sever
combin
immunodefici
scid
genet
heterogen
immun
disord
character
dramat
reduct
number
function
lymphocyt
well
function
quantit
defect
b
lymphocyt
natur
killer
nk
cell
immunocompet
newborn
effect
tcell
immun
rapidli
reject
histocompat
leukocyt
antigen
hla
mismatch
matern
lymphocyt
bidirect
pass
mother
foetu
human
placenta
scid
newborn
fail
reject
circul
matern
cell
matern
deriv
engraft
cell
whose
number
rang
blood
sever
thousandml
function
incompet
show
limit
prolif
respons
mitogen
also
usual
express
restrict
tcell
receptor
repertoir
find
suggest
transplacent
passag
small
number
cell
success
expand
host
major
case
scid
patient
matern
tcell
engraft
asymptomat
approxim
mild
symptom
sign
eosinophilia
elev
liver
enzym
periport
tcell
infiltr
erythema
skin
tcell
infiltr
hepat
cutan
manifest
similar
observ
graft
versu
host
diseas
gvhd
develop
hematopoiet
stem
cell
transplant
hsct
matern
tcell
engraft
previous
describ
best
known
form
scid
result
mutat
gene
encod
adenosin
deaminas
ada
adascid
patient
matern
cell
could
probabl
kill
rais
level
deoxyadenosin
dado
toxic
metabol
substrat
accumul
defici
impair
ada
activ
affect
children
usual
present
typic
clinic
immunolog
manifest
scid
patient
togeth
peculiar
featur
describ
patient
adascid
matern
tcell
engraft
complic
diagnosi
rare
diseas
italian
girl
born
fullterm
unev
pregnanc
nonconsanguin
parent
refer
hospit
histori
frequent
bronchiol
associ
dermat
mycosi
clinic
immunolog
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
c
l
patient
immunolog
character
perform
follow
scheme
appli
case
suspect
immunodefici
immunophenotyp
perform
facscanto
ii
cytomet
combin
analysi
data
facsdiva
softwar
bd
bioscenc
lymphocyt
prolifer
determin
h
thymidin
incorpor
assay
stimul
phytohemoagglutinin
pha
monoclon
antibodi
moab
anti
moab
plu
ada
activ
adenin
nucleotid
content
red
blood
cell
ada
activ
red
blood
cell
rbc
lysat
assay
spectrophotometr
measur
rate
ada
absorb
chang
nm
valu
express
ug
hemoglobin
hb
dado
nucleotid
rbc
daxp
quantifi
high
perform
liquid
chromatographi
measur
level
adenosin
ado
dado
form
treat
neutral
acid
extract
alkalin
phosphatas
venom
phosphodiesteras
matern
tcell
engraft
posthsct
chimer
statu
evalu
use
identifil
plu
pcr
amplif
kit
life
technolog
inc
foster
citi
ca
short
tandem
repeat
multiplex
assay
amplifi
tetranucleotid
repeat
loci
amelogenin
gender
determin
marker
fluoresc
pcr
product
load
genet
analyz
result
analyz
use
genemapp
id
softwar
amplif
ada
exon
genom
dna
perform
use
primer
condit
previous
report
although
appear
healthi
birth
day
life
child
develop
onychomycosi
hand
feet
treat
antibiot
thirti
day
later
present
skin
lesion
impetigo
purul
exud
eye
bronchiol
caus
infect
agent
identifi
month
life
pulmonari
function
worsen
white
blood
cell
neutrophil
lymphocyt
lymphocyt
phenotyp
reveal
profound
lymphopenia
vs
pediatr
healthi
popul
report
tabl
month
life
child
show
typic
clinic
present
scid
sever
laboratori
find
relat
diseas
lack
typic
physic
radiolog
featur
adascid
therefor
variabl
number
tandem
repeat
analysi
reveal
lymphocyt
matern
origin
ada
activ
ug
hb
healthi
control
rang
ug
hb
show
presenc
residu
absent
enzymat
activ
surprisingli
valu
toxic
ada
metabolit
daxp
rbc
healthi
control
daxp
rang
b
rbc
daxp
healthi
control
daxp
month
age
diagnosi
adascid
made
dna
sequenc
perform
primer
design
amplifi
ada
code
exon
entir
intron
two
mutat
identifi
ada
gene
second
mutat
previous
describ
literatur
enzym
replac
therapi
ukg
twice
weekli
pegada
togeth
mgkg
twice
monthli
intraven
immunoglobulin
immedi
initi
diagnosi
therapi
engraft
matern
cell
child
drop
toxic
ada
metabolit
decreas
daxp
rbc
daxp
within
month
final
month
life
recoveri
coronaviru
infect
diagnost
month
underw
hsct
match
unrel
donor
mud
hlamatch
sinc
hlaident
famili
donor
avail
patient
receiv
reducedintens
myeloabl
condit
mgm
fludarabin
gm
treosulfan
anti
thymocyt
globulin
atg
infus
cell
platelet
neutrophil
engraft
achiev
day
hsct
respect
complet
donor
chimer
detect
lymphocyt
polymorphonucl
cell
day
hsct
lymphocyt
prolifer
mitogen
normal
month
post
hsct
pha
cpm
moab
cpm
moab
plu
cpm
due
use
atg
part
condit
full
immunolog
reconstitut
achiev
month
post
hsct
cell
nk
child
month
old
good
health
without
sign
gvhd
scid
diseas
difficult
recogn
infant
earlyonset
sever
respiratori
tract
infect
infecti
diseas
caus
opportunist
pathogen
chronic
diarrhea
failur
thrive
common
present
pictur
child
affect
scid
sever
clinic
present
depend
compromis
immun
system
matern
engraft
common
featur
scid
patient
engraft
lymphocyt
contain
high
fraction
function
regulatori
cell
confer
hightoler
capac
appear
repres
toler
advantag
besid
sever
immunodefici
matern
cell
could
provid
degre
immun
therefor
may
protect
child
sever
infect
commonli
accept
presenc
larg
amount
matern
cell
scid
patient
occur
host
cell
lack
thought
disprov
recent
find
longterm
coexist
engraft
matern
cell
autolog
cell
scid
patient
janu
kinas
jak
mutat
patient
mild
omenn
syndrom
phenotyp
rare
case
engraft
matern
cell
might
persist
long
time
lead
partial
reconstitut
immun
function
delay
clinic
present
scid
contest
matern
engraft
test
enzymat
ada
assay
perform
better
defin
diseas
presenc
matern
engraft
cell
residu
ada
activ
enzym
patient
could
delay
identif
adascid
laboratori
test
show
low
number
cell
toxic
ada
metabolit
suggest
diagnosi
adascid
molecular
analysi
ada
gene
allow
conclus
diagnosi
diseas
ada
metabolit
toxic
effect
differ
organ
system
notabl
immun
system
still
entir
clear
howev
whether
lymphocyt
adadefici
patient
intrins
abnorm
whether
observ
defect
secondari
effect
deoxyadenosin
triphosph
dado
accumul
therefor
patient
ada
metabolit
nt
clear
toxic
effect
lymphocyt
matern
origin
conclus
describ
case
matern
engraft
cell
infant
adascid
type
immunodefici
engraft
cell
never
describ
patient
show
typic
earlyonset
adadefici
scid
symptom
molecular
analysi
ada
gene
allow
diseas
diagnosi
therefor
fast
correct
diagnosi
crucial
earli
treatment
contrari
expect
life
children
would
year
moreov
hsct
high
rate
cure
depend
infecti
statu
transplant
age
patient
transplant
youngest
go
better
accordingli
patient
earli
hsct
provid
definit
treatment
although
posthsct
acut
gvhd
develop
significantli
scid
patient
matern
engraft
cell
patient
show
complic
studi
approv
comitato
etico
di
brescia
protocol
number
np
inform
consent
obtain
parent
adascid
patient
